Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | MTTP | P55157 | 14/20 | 0.51 |
| ▸ | APOB | P04114 | 9/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804178 | 0.92 | MTTP (0.52) | CYP11B1CYP11B2MTTPAPOBSMO | |
| SCHEMBL6666916 | 0.92 | CYP11B1 (0.55) | CYP11B1CYP11B2MTTPAPOBHTR2A | |
| SCHEMBL6804697 | 0.89 | SMO (0.54) | MTTPAPOBHTR2AHTR2CSMO | |
| SCHEMBL6804688 | 0.86 | SMO (0.61) | MTTPAPOBHTR2AHTR2CSMO | |
| SCHEMBL6805191 | 0.85 | SMO (0.51) | MTTPAPOBSMO | |
| SCHEMBL6647338 | 0.84 | APOB (0.56) | MTTPAPOBSMO | |
| SCHEMBL6665703 | 0.84 | CYP11B1 (0.49) | CYP11B1CYP11B2MTTPAPOBHTR2A | |
| SCHEMBL6644284 | 0.83 | SMO (0.49) | MTTPAPOBSMO | |
| SCHEMBL6809825 | 0.82 | SMO (0.50) | MTTPAPOBSMO | |
| SCHEMBL6667700 | 0.82 | SMO (0.49) | MTTPAPOBSMOEIF2AK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | CYP11B1 61/4885CYP11B2 96/4885MTTP 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.